SMG8 CRISPR Activation Plasmid (h): sc-408902-ACT

SMG8 encodes a core component of the SMG1C complex that regulates nonsense-mediated mRNA decay (NMD), a conserved RNA surveillance pathway that detects and degrades transcripts containing premature termination codons. By modulating SMG1 kinase activity and coordinating UPF1 phosphorylation dynamics, SMG8 helps couple translation termination to mRNP remodeling and targeted mRNA turnover. Through these mechanisms, SMG8 contributes to transcriptome quality control, proteostasis, and stress-responsive gene expression programs. Dysregulated NMD and SMG8-linked perturbations in RNA metabolism have been associated with altered cellular homeostasis and are studied in contexts including neurodevelopmental phenotypes and cancer-relevant gene expression changes.

SMG8 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SMG8 expression without altering the underlying DNA sequence.

SMG8 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SMG8 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SMG8 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SMG8 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SMG8 locus and enabling the study of SMG8-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SMG8 pathway restoration in tumor cells with silenced or reduced SMG8 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.